Invasive oesophageal candidiasis: current and developing treatment options.

Abstract:

:Oesophageal candidiasis is frequently one of the first signs of HIV infection, and a marker of HIV disease. Approximately 10% of patients with AIDS or other immunodeficiency, whether due to an underlying disease, chemotherapy or radiation therapy, will experience oesophageal candidiasis during their lifetime. In addition, unless the underlying immunodeficiency is corrected, approximately 60% of patients will experience a relapse within 6 months of the initial infection. The systemic azoles have gradually replaced the use of amphotericin B for oesophageal candidiasis, and are generally safely used and effective agents for this infection. A concern in some of these patients is the appearance of antifungal-refractory oesophageal candidiasis, which frequently leads to a vicious cycle of poor oral intake, weight loss, malnutrition and wasting syndrome, with occasional mortality due to malnutrition. Newer antifungals such as voriconazole and caspofungin, which are more potent in vitro and have a broader spectrum of activity, including activity against fluconazole-resistant Candida species are a welcome addition to the antifungal armamentarium that may be used in the management of refractory mucosal candidiasis.

journal_name

Drugs

journal_title

Drugs

authors

Vazquez JA

doi

10.2165/00003495-200363100-00004

subject

Has Abstract

pub_date

2003-01-01 00:00:00

pages

971-89

issue

10

eissn

0012-6667

issn

1179-1950

pii

63104

journal_volume

63

pub_type

杂志文章,评审

相关文献

DRUGS文献大全
  • The pharmacodynamics and pharmacokinetics of multiple doses of the new H2-receptor antagonist, roxatidine acetate, in healthy men.

    abstract::Roxatidine acetate (HOE 760, TZU 0460) is a new H2-receptor antagonist which is more potent than cimetidine and ranitidine. A randomised, double-blind, placebo-controlled study was conducted in healthy men to determine the effects of multiple oral doses of roxatidine acetate on unstimulated gastric acid secretion, and...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198800353-00011

    authors: Lassman HB,Ho I,Puri SK,Sabo R,Scheffler MR

    更新日期:1988-01-01 00:00:00

  • Targeting ROS1 Rearrangements in Non-small Cell Lung Cancer: Crizotinib and Newer Generation Tyrosine Kinase Inhibitors.

    abstract::ROS1 gene rearrangements exist in 1-2% of non-small cell lung cancers, typically occurring in younger, never or light smokers with adenocarcinoma. ROS1 gene fusions are potent oncogenic drivers, the presence of which results in the susceptibility of tumours to ROS1-targeted therapy. Crizotinib was the first tyrosine k...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01164-3

    authors: Morris TA,Khoo C,Solomon BJ

    更新日期:2019-08-01 00:00:00

  • Retention in care and medication adherence: current challenges to antiretroviral therapy success.

    abstract::Health behaviors such as retention in HIV medical care and adherence to antiretroviral therapy (ART) pose major challenges to reducing new HIV infections, addressing health disparities, and improving health outcomes. Andersen's Behavioral Model of Health Service Use provides a conceptual framework for understanding ho...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-015-0373-2

    authors: Holtzman CW,Brady KA,Yehia BR

    更新日期:2015-04-01 00:00:00

  • Diuretics. Clinical pharmacology and therapeutic use (Part II).

    abstract::25 years have elapsed since the introduction of the first effective oral diuretic, chlorothiazide. Diuretics are now amongst the most widely prescribed drugs in clinical practice worldwide. Availability of these drugs has not only brought therapeutic benefit to countless numbers of patients but it has at the same time...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198529020-00003

    authors: Lant A

    更新日期:1985-02-01 00:00:00

  • Glycaemia control in diabetes mellitus. Towards the normal profile?

    abstract::The Diabetes Control and Complications Trial and the Stockholm Study have conclusively demonstrated that improving the blood glucose control in patients with insulin-dependent diabetes mellitus (IDDM) reduces the risk of developing retinopathy, nephropathy and neuropathy. Each patient with IDDM should be carefully eva...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199447040-00005

    authors: Zimmerman BR

    更新日期:1994-04-01 00:00:00

  • Ofloxacin. A reappraisal of its use in the management of genitourinary tract infections.

    abstract:UNLABELLED:Ofloxacin is an established fluoroquinolone agent which achieves good concentrations in genitourinary tract tissues and fluids. It has good in vitro activity against most Enterobacteriaceae, Staphylococcus saprophyticus, methicillin-susceptible S. aureus, Neisseria gonorrhoeae, Chlamydia trachomatis and Haem...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856050-00015

    authors: Onrust SV,Lamb HM,Balfour JA

    更新日期:1998-11-01 00:00:00

  • Oral delayed-release mesalazine: a review of its use in ulcerative colitis and Crohn's disease.

    abstract:UNLABELLED:Oral delayed-release mesalazine is an enteric-coated formulation which releases mesalazine in the terminal ileum and colon. Up to 74% of patients with mild to moderately active ulcerative colitis experience endoscopic or symptomatic improvement (including remission) or both when treated with oral delayed-rel...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199957030-00013

    authors: Prakash A,Markham A

    更新日期:1999-03-01 00:00:00

  • Levodopa/Carbidopa Enteral Suspension: A Review in Advanced Parkinson's Disease.

    abstract::An enteral suspension (ES)/intestinal gel formulation of levodopa/carbidopa (hereafter referred to as levodopa/carbidopa ES) [Duodopa® (EU); Duopa™ (USA)] has been developed to overcome the fluctuating plasma levodopa concentrations associated with oral levodopa/carbidopa formulations. In various countries, including ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-019-01201-1

    authors: Hoy SM

    更新日期:2019-10-01 00:00:00

  • Lemborexant: First Approval.

    abstract::Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01276-1

    authors: Scott LJ

    更新日期:2020-03-01 00:00:00

  • Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome.

    abstract::Several large-scale clinical trials have assessed the efficacy of atorvastatin in the primary and secondary prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. In primary prevention, CARDS (Collaborative Atorvastatin Diabetes Study) showed that atorvastatin 10 mg/day (vs p...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200767001-00005

    authors: Arca M

    更新日期:2007-01-01 00:00:00

  • Lanreotide Autogel: a review of its use in the management of acromegaly.

    abstract::Lanreotide Autogel (ATG) [Somatuline Depot] is a novel, long-acting preparation of the somatostatin analogue lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels. It is indicated for the management of acromegaly and, relative to most...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200868050-00013

    authors: Croxtall JD,Scott LJ

    更新日期:2008-01-01 00:00:00

  • Systematic review and guide to selection of selective serotonin reuptake inhibitors.

    abstract::A meta-analysis of 20 short term comparative studies of 5 selective serotonin reuptake inhibitors (SSRIs; citalopram, fluoxetine, fluvoxamine, paroxetine and sertraline) has shown no difference in efficacy between individual compounds but a slower onset of action of fluoxetine. There were suggestions that fluoxetine c...

    journal_title:Drugs

    pub_type: 杂志文章,meta分析

    doi:10.2165/00003495-199957040-00005

    authors: Edwards JG,Anderson I

    更新日期:1999-04-01 00:00:00

  • 5-Methoxypsoralen. A review of its effects in psoriasis and vitiligo.

    abstract:UNLABELLED:5-Methoxypsoralen, a naturally occurring linear furocoumarin, has been successfully used in combination with ultraviolet (UV) A irradiation [psoralen plus UV (PUVA)] to manage psoriasis and vitiligo. In patients and volunteers, PUVA 5-methoxypsoralen causes a dose-related increase in cutaneous photosensitivi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856040-00015

    authors: McNeely W,Goa KL

    更新日期:1998-10-01 00:00:00

  • Pharmacotherapy for overactive bladder: an evidence-based approach to selecting an antimuscarinic agent.

    abstract::Multiple drugs are now available for the treatment of overactive bladder. Currently, the pharmacological approach is to deal with the problem at the neuromuscular junction by attempting to stop the activity of the neurotransmitter with antimuscarinic medications. This article reviews the positive and negative aspects ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200666100-00005

    authors: Appell RA

    更新日期:2006-01-01 00:00:00

  • New and Emerging Therapies for Alopecia Areata.

    abstract::Alopecia areata (AA) is an autoimmune condition that affects up to 2% of the general population. Currently available treatment options for AA are of limited efficacy and can be associated with adverse effects. The advancement in understanding of the genetic and molecular mechanisms of AA has led to the development of ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-020-01293-0

    authors: Pourang A,Mesinkovska NA

    更新日期:2020-05-01 00:00:00

  • Glipizide: a review of its pharmacological properties and therapeutic use.

    abstract::Glipizide is a 'second generation' oral hypoglycaemic agent similar in potency to glibenclamide. It is completely absorbed after oral administration and has a rapid onset of action, but the duration of its hypoglycaemic effect is shorter than that of glibenclamide. It is rapidly metabolised to inactive metabolites whi...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-197918050-00001

    authors: Brogden RN,Heel RC,Pakes GE,Speight TM,Avery GS

    更新日期:1979-11-01 00:00:00

  • Dapoxetine: in premature ejaculation.

    abstract::Dapoxetine, a selective serotonin reuptake inhibitor, is the first oral pharmacological agent indicated for the treatment of men aged 18-64 years with premature ejaculation. In four randomized, double-blind, placebo-controlled, multicentre studies of 12-24 weeks' duration, oral dapoxetine 30 or 60 mg (administered as ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11204750-000000000-00000

    authors: Hoy SM,Scott LJ

    更新日期:2010-07-30 00:00:00

  • Durability and rapidity of response to anakinra in patients with rheumatoid arthritis.

    abstract::Rheumatoid arthritis (RA) is a chronic and progressive inflammatory disease that ultimately leads to disability and functional decline. Because patients usually develop RA in mid-life, they may experience its consequences for 20-30 years or longer. Proinflammatory cytokines, notably interleukin (IL)-1 and tumour necro...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200464220-00001

    authors: Schiff MH

    更新日期:2004-01-01 00:00:00

  • Quinidine and digoxin. An important interaction.

    abstract::An increase in serum digoxin concentration occurs in 90% of patients given quinidine. On average, the serum digoxin doubles during treatment with therapeutic doses of quinidine. Almost every patient treated with quinidine will have a decrease in the renal clearance of digoxin and many will have a decrease in the volum...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-198224030-00003

    authors: Bigger JT Jr,Leahey EB Jr

    更新日期:1982-09-01 00:00:00

  • Does effective management of sleep disorders reduce depressive symptoms and the risk of depression?

    abstract::The link between co-morbid insomnia and depression has been demonstrated in numerous groups. Insomnia has been associated with: (1) an increased risk of developing subsequent depression; (2) an increased duration of established depression; and (3) relapse following treatment for depression. In addition, specific insom...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/11531130-000000000-00000

    authors: Riemann D,Workshop Participants.

    更新日期:2009-01-01 00:00:00

  • Critical appraisal of ramucirumab (IMC-1121B) for cancer treatment: from benchside to clinical use.

    abstract::Although antiangiogenic treatments have produced milestone advances in the treatment of several diseases, and have significantly extended the median survival of cancer patients, these agents share some weaknesses, including a limited impact on the overall cure rate, a fleeting effect because of redundant pathways or e...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.1007/s40265-013-0154-8

    authors: Aprile G,Bonotto M,Ongaro E,Pozzo C,Giuliani F

    更新日期:2013-12-01 00:00:00

  • Felodipine in hypertensive patients. A dose finding study in patients refractory to beta-blocker monotherapy.

    abstract::In a double-blind study, 128 patients with essential hypertension, refractory to beta-blocker monotherapy, were randomised to 1 of 4 treatment groups. Felodipine 2.5 mg twice daily, 5mg twice daily, 10mg twice daily or matched placebo twice daily were administered in addition to the beta-blocker for 4 weeks. Mean supi...

    journal_title:Drugs

    pub_type: 临床试验,杂志文章,随机对照试验

    doi:10.2165/00003495-198700343-00023

    authors: Sluiter HE

    更新日期:1987-01-01 00:00:00

  • Aggravation of ventricular arrhythmia. A drug-induced complication.

    abstract::Each antiarrhythmic agent can cause side effects, but most of these are easily recognised by the patient or physician. However, one potentially serious side effect common to all of these drugs is aggravation of ventricular arrhythmia. Often this is without symptoms and goes unrecognised by the patient. It occurs in 11...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.2165/00003495-198500294-00009

    authors: Podrid PJ

    更新日期:1985-01-01 00:00:00

  • Current treatment recommendations for topical burn therapy.

    abstract::Infections in burn patients continue to be the primary source of morbidity and mortality. Topical antimicrobial therapy remains the single most important component of wound care in hospitalised burn patients. The goal of prophylactic topical antimicrobial therapy is to control microbial colonisation and prevent burn w...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040030-00004

    authors: Monafo WW,West MA

    更新日期:1990-09-01 00:00:00

  • Adverse effects and drug interactions of antithrombotic agents used in prevention of ischaemic stroke.

    abstract::Stroke is the third most common cause of death in the US. Primary prevention of stroke can be achieved by control of risk factors including hypertension, diabetes mellitus, elevated cholesterol levels and smoking. Approximately one-third of all ischaemic strokes occur in patients with a history of stroke or transient ...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200565040-00003

    authors: Weinberger J

    更新日期:2005-01-01 00:00:00

  • Balsalazide: a review of its therapeutic use in mild-to-moderate ulcerative colitis.

    abstract:UNLABELLED:The aminosalicylate balsalazide is a prodrug which is metabolised by bacterial azo reductases in the colon to release its therapeutically active moiety mesalazine [mesalamine (US) or 5-aminosalicylic acid] and an inert carrier molecule. The systemic absorption of balsalazide and its metabolites is not requir...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-200262110-00010

    authors: Muijsers RB,Goa KL

    更新日期:2002-01-01 00:00:00

  • Osteoarthritis 1991. Current drug treatment regimens.

    abstract::Osteoarthritis, the most common rheumatic disease, presents the clinician with a major therapeutic and management task. The chronic and progressive course of the disease is punctuated by pain, declining function and escalating disability. This article attempts to deal with the pharmacological therapeutic options avail...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199141020-00005

    authors: al Arfag A,Davis P

    更新日期:1991-02-01 00:00:00

  • Drugs and receptors. An overview of the current state of knowledge.

    abstract::This paper reviews the theoretical concepts and methods utilised with isolated tissues to characterise drugs and drug receptors. Specifically the impact, on the in vitro measurement of agonist affinity and relative efficacy, of the idea that receptors bind to transduction proteins in the lipid bilayer of the cell memb...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199040050-00003

    authors: Kenakin T

    更新日期:1990-11-01 00:00:00

  • [Evaluation of the impact of peripheral obliterative arteriopathy on quality of life].

    abstract::Peripheral arterial occlusive disease is a common condition with possible serious consequences. It is usually diagnosed at the intermittent claudication stage. There are 2 objectives of treatment: to prevent ischaemic attacks and to improve quality of life. Treatment efficacy is, however, usually evaluated only in ter...

    journal_title:Drugs

    pub_type: 杂志文章,评审

    doi:10.2165/00003495-199856003-00004

    authors: Marquis P

    更新日期:1998-01-01 00:00:00

  • Why Biologics and Biosimilars Remain So Expensive: Despite Two Wins for Biosimilars, the Supreme Court's Recent Rulings do not Solve Fundamental Barriers to Competition.

    abstract::Biologics and biosimilars are medicines made from living cells that treat common and serious diseases such as cancer, diabetes, rheumatoid arthritis, and other inflammatory diseases. They are highly targeted, efficacious, and represent an increasingly important part of physicians' armamentaria in the combat against th...

    journal_title:Drugs

    pub_type: 杂志文章

    doi:10.1007/s40265-018-1009-0

    authors: Chen BK,Yang YT,Bennett CL

    更新日期:2018-11-01 00:00:00